1. Show article details.

    IMMUNOMEDICS TO HOST CONFERENCE CALL AND WEBCAST ON APRIL 6, 2020 TO PROVIDE CLINICAL AND CORPORATE UPDATE

    GlobeNewswire – 5:00 PM ET 04/03/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Company will host a conference call and live audio webcast on Monday, April 6, 2020 at 8:00 a.m. Eastern Time to provide a clinical development and general corporate update.   To access the conference call, please dial 303-2523 or 237-1755 using the Conference ID 8348877.

  2. Show article details.

    BRIEF-Immunomedics Provides COVID-19 Business Continuity Update, Affirms 2020 Strategic Priorities, And Shares Research And Development And Regulatory Update

    Reuters – 8:30 AM ET 03/25/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES RESEARCH AND DEVELOPMENT AND REGULATORY UPDATE. * Immunomedics Inc (IMMU) - REITERATES PLAN FOR TOPLINE UPDATE ON FULL 100-PATIENT COHORT OF TROPHY U-01 AT MEDICAL CONFERENCE IN H2 2020.

  3. Show article details.

    IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE

    GlobeNewswire – 8:00 AM ET 03/25/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today provided a business update in lieu of the changes brought upon by the novel coronavirus pandemic.   “We are acutely focused on macro and systemic developments and continue to adjust our business operations accordingly.

  4. Show article details.

    BRIEF-Immunomedics Reports Q4 Loss Per Share $0.50

    Reuters – 6:02 PM ET 02/27/2020

    Immunomedics Inc (IMMU): * IMMUNOMEDICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 RESULTS AND PROVIDES CORPORATE UPDATE. * Q4 LOSS PER SHARE $0.50. * Q4 EARNINGS PER SHARE ESTIMATE $-0.46 -- REFINITIV IBES DATA. * Q4 REVENUE $300,000. * Q4 REVENUE ESTIMATE $533,000 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:

  5. Show article details.

    Immunomedics Appoints Robert W. Azelby to Board of Directors

    GlobeNewswire – 4:10 PM ET 02/27/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the appointment of Robert W. Azelby to the Company’s board of directors. “I am excited to join Immunomedics (IMMU) at an inflection point as the Company is preparing for its first potential commercial launch in its history,” said Mr. Azelby.

  6. Show article details.

    Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update

    GlobeNewswire – 4:00 PM ET 02/27/2020

    TROPHY U-01 expanded to combine sacituzumab govitecan with Keytruda® in I/O naïve patients New investigator-initiated study launched to evaluate sacituzumab govitecan in recurrent endometrial cancer Nearing completion on preparations for U.S. commercial launch if BLA is approved MORRIS PLAINS, N.J., Feb. 27, 2020 -- Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of ant...

  7. Show article details.

    Immunomedics to Participate in Upcoming Healthcare Conferences  

    GlobeNewswire – 8:00 AM ET 02/25/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Company will participate in fireside chats at the following healthcare conferences: Live audio webcast of the fireside chats will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also participate in one-on-one meetings with i...

  8. Show article details.

    Immunomedics to Report Results for the Fourth Quarter and Full Year 2019 and Host Conference Call and Webcast on February 27, 2020

    GlobeNewswire – 8:00 AM ET 02/20/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Thursday, February 27, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the fourth quarter and full year 2019 and provide a corporate update.

  9. Show article details.

    Immunomedics Appoints Dr. Loretta Itri Chief Medical Officer

    GlobeNewswire – 8:00 AM ET 02/14/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the appointment of Loretta Itri, M.D. as chief medical officer, effective today. “I am thrilled Loretta has agreed to join us as our permanent CMO,” remarked Dr. Behzad Aghazadeh, executive chairman. Dr. Itri commented, “It is my distinct pleasure to formally join Immunomedics (IMMU) as CMO.

  10. Show article details.

    Immunomedics to Participate in Guggenheim Healthcare Talks | Oncology Day

    GlobeNewswire – 8:00 AM ET 02/06/2020

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, executive chairman, is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 2:00 p.m. Eastern Time.

  11. Show article details.

    FOCUS-Drug developers take fresh aim at 'guided-missile' cancer drugs

    Reuters – 6:00 AM ET 01/06/2020

    Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows.

  12. Show article details.

    Immunomedics Announces FDA Acceptance for Filing of Biologics License Application Resubmission for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer

    GlobeNewswire – 8:00 AM ET 12/26/2019

    Prescription Drug User Fee Act target action date set for June 2, 2020 Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the U.S. Food and Drug Administration has accepted for filing the Company’s Biologics License Application seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic t...

  13. Show article details.

    Immunomedics Announces Closing of Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 12/09/2019

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the closing of its previously announced underwritten public offering of common stock.

  14. Show article details.

    Immunomedics Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 8:29 PM ET 12/04/2019

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a public offering price of $17.50 per share, representing gross proceeds of approximately $250 million.

  15. Show article details.

    Immunomedics Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 12/03/2019

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced it has commenced an underwritten public offering of $250,000,000 of shares of its common stock.

  16. Show article details.

    Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

    GlobeNewswire – 8:00 AM ET 12/03/2019

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced the resubmission of its Biologics License Application to the U.S. Food and Drug Administration seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metasta...

  17. Show article details.

    Immunomedics to Present at Upcoming Healthcare Conferences

    GlobeNewswire – 8:00 AM ET 11/13/2019

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to present at the following healthcare conferences: Live audio webcast of the presentation and the fireside chat will be accessible from the Company’s website at https://immunomedics.com/investors/. The Company will also pa...

  18. Show article details.

    Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update

    GlobeNewswire – 4:00 PM ET 10/30/2019

    TROPHY-U-01 Reached Target Enrollment in Cisplatin-Eligible Cohort of 100 Patients First NSCLC Patient Dosed in Trop-2-Enriched TROPiCS-03 Study BLA Resubmission Targeted for Late November/Early December 2019 MORRIS PLAINS, N.J., Oct. 30, 2019 -- Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today reported financial results for the third quar...

  19. Show article details.

    Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019

    GlobeNewswire – 8:00 AM ET 10/23/2019

    Immunomedics, Inc. (IMMU) , a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, October 30, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the third quarter of 2019 and provide a corporate update. To access the conference call, please dial 303-2523 or 237-1755 using the Conference ID 3164368.

Page:

Today's and Upcoming Events

  • May
    11

    IMMU to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    27

    IMMU announced Q4 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.